Pharma BD Deal Intelligence

Eli Lilly and Company / Stipple Bio

2026 · Licensing/Option · $5.9B · Complete

Eli Lilly entered a multi-target, multi-modality strategic research collaboration and exclusive global license agreement with Cambridge, Massachusetts-based Stipple Bio to discover and commercialize cancer medicines directed at tumor-specific cell-surface epitopes identified on Stipple's Pointillist platform. Lilly receives exclusive worldwide rights to develop and commercialize resulting products. Stipple receives an undisclosed upfront payment plus an equity investment from Lilly, aggregate research, development and commercial milestone payments of up to $5.9 billion, and tiered royalties on product sales. The stated scientific rationale is to target epitopes present only on cancer cells to avoid the on-target/off-tumor toxicity that has limited prior cell-surface-directed oncology therapeutics.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →